Johnson & Johnson intends to separate its high-margin but risky prescription-drugs and medical-devices business from its storied but slower-growing consumer group, creating two publicly traded companies.
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
